![]() |
|
September 19, 2005 |
CONTACT: Susanne Hartman (215) 349-5964 susanne.hartman@uphs.upenn.edu |
|
Penn Lab Performs Its 2500th Endomyocardial Biopsy
Procedure (Philadelphia, PA) - Another milestone has been reached
in the Heart Failure and Transplantation Program of the University
of Pennsylvania Health System. In continuing to meet the goals
of providing centralized outpatient care services for heart failure and
cardiac transplant patients -- a procedure area was built and opened in
July 2003 in the Penn Tower building. It was built in this location to
accommodate our patients who were already receiving cardiac care services
including physician and nursing visits, echocardiography, phlebotomy,
exercise testing, financial counseling, social services and research.
On September 13, 2005, the heart transplant staff performed the 2500th
endomyocardial biopsy procedure at this site. This effort involves coordination
of services by staff from the heart failure and transplantation program,
the catheterization lab, as well as radiology. Prior to the opening of
the procedure area, patients went to the HUP cardiac catheterization laboratory
located in the hospital for their biopsy. ### PENN Medicine is a $2.7 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System. Penn’s School of Medicine is ranked #2 in the nation for receipt
of NIH research funds; and ranked #4 in the nation in U.S. News &
World Report’s most recent ranking of top research-oriented medical
schools. Supporting 1,400 fulltime faculty and 700 students, the School
of Medicine is recognized worldwide for its superior education and training
of the next generation of physician-scientists and leaders of academic
medicine. |
|
|
|